SynthesisFrontiers in medicine2025
Trends and hotspots in pulmonary fibrosis biomarker research: a bibliometric analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNA regulation in pulmonary fibrosis: a bibliometric analysis of global research trends, collaborative networks, and emerging frontiers.Frontiers in medicine · 2026Pooled it
- Mechanistic insights and therapeutic potential of sphingosine‑1‑phosphate in the development of pulmonary fibrosis (Review).Molecular medicine reports · 2026Review
- Plasma proteomic and machine learning models for differentiating idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease: findings from a prospective cohort.Respiratory research · 2026Article
- Comparative Analysis of Lysis Buffers for Enhanced Proteomic and Glycoproteomic Profiling.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary fibrosis is a fatal disease characterized by progressive scarring of lung tissue, with a complex pathogenesis and limited therapeutic options. The identification of robust biomarkers is critical for addressing key clinical challenges, including delayed diagnosis and poor prognostic assessment. Methods: This study systematically analyzes global research trends and emerging hotspots in pulmonary fibrosis biomarkers by examining literature from 2001 to 2024 indexed in the Web of Science Core Collection. Utilizing a suite of bibliometric tools including VOSviewer, CiteSpace, Bibliometrix, Scimago Graphica, and OriginPro 2021, this work provides the first comprehensive insight into the evolving landscape of biomarker research in pulmonary fibrosis. Results: This study included a total of 2,519 articles and reviews related to pulmonary fibrosis biomarkers. Since 2005, publication trends in this field have steadily increased. Research on pulmonary fibrosis biomarkers has involved 71 countries, 3,036 institutions, 760 journals, and over 14,000 researchers. China produced the highest number of publications ( Conclusion: The clinical application of gene and imaging biomarkers achieved through the integration of multiple parameters and multi-omics fusion represents a promising future trend and emerging hotspot in pulmonary fibrosis biomarker research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.